Video

Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19

Author(s):

Mark Fleury, PhD

Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.

Mark Fleury, PhD, principal of policy development, American Cancer Society Cancer Action Network, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.

The COVID-19 pandemic presented a significant need to rapidly advance the utility of decentralized clinical trials, says Fleury. Historically, the oncology field anticipated that decentralized clinical trials would be an important aspect of offering patients more accessible and convenient clinical trial options away from the conventional clinical trial setting, Fleury explains.

It is important that the lessons learned from the pandemic, as well as the use of tools developed for decentralized clinical trials, continue even beyond the COVID-19 pandemic, concludes Fleury.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Related Content
Paul G. Kluetz, MD
May 9th 2023

Decentralization Efforts Could Engage Community Oncologists

Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer
June 6th 2022

Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer

Electra D. Paskett, PhD
March 24th 2023

Delays in Cancer Screenings Due to COVID-19 May Result in Trend Toward Excess Deaths

Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients
June 2nd 2022

Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients

Maurie Markman, MD
October 26th 2022

Time Required to Address Scientific Questions Generates an Information Dilemma

Mili Arora, MD
July 8th 2022

In the Trenches With the Fellows